ACE Reno™ Clinical Trial — Human Evidence Backing Next-Gen Kidney Support

 

ACE Reno™, powered by our proprietary Pico Cell Matrix technology, is currently being evaluated in a Phase 4 human clinical study — demonstrating our commitment to rigorous, evidence-based development of regenerative peptide-based therapies.

  • Study Title: ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases
  • Registry ID: NCT07187713 – publicly searchable on ClinicalTrials.gov
  • Phase: Phase 4 (post-market clinical evaluation)
  • Design: Prospective, open-label, single-arm clinical study
  • Duration: 12-week treatment + 4-week safety follow-up
  • Population: ~300 adults with nephropathy/CKD of various causes

What We’re Measuring

Primary Endpoint
✔ Change in urinary albumin-to-creatinine ratio (ACR) — a key marker of kidney damage.

Secondary Endpoints
✔ Trends in estimated glomerular filtration rate (eGFR) (kidney filtering efficiency)
✔ Proteinuria levels, blood pressure changes, patient-reported outcomes and safety/tolerability.

 

What This Trial Means for ACE Reno™

  • First-of-its-kind human study of our Pico Cell Matrix technology applied to kidney function, setting a new bar for evidence in regenerative peptide therapies.
  • Conducted under Good Clinical Practice (GCP) standards, with structured endpoints and scheduled assessments — not anecdote but data.
  • Designed to assess meaningful changes in kidney function markers over a 12-week course.

Product Science

ACE Reno™ is an oral sublingual solution of standardized bioactive peptides and amino acids — not genetic material — formulated using the ACE Pico Cell Matrix process.

These peptides are selected to engage pathways relevant to kidney structure and function, including mechanisms associated with fibrosis modulation, tissue repair, and endothelial support.

Current Status & Next Steps

The trial is actively recruiting adult participants (18 +) with a range of kidney conditions, from microalbuminuria to chronic kidney disease across multiple etiologies.

Why This Matters

This clinical evaluation reinforces that ACE Reno™ isn’t just promising in concept — it’s supported by structured, registered clinical research designed to demonstrate objective outcomes in real patients under monitored conditions.